TipRanks
Liminatus Pharma (LIMN)
NASDAQ:LIMN
US Market
LIMN
Liminatus Pharma
RESEARCH TOOLSreports

Liminatus Pharma (LIMN) Income Statement

115 Followers

Liminatus Pharma Income Statement

Last quarter (Q2 2026), Liminatus Pharma's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q2, Liminatus Pharma's net income was $-1.41M. See Liminatus Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 2.97M$ 2.91M$ 2.59M$ 2.71M$ 2.53M
Depreciation and Amortization
$ 1.83K$ 0.00$ 0.00$ 1.00K$ 0.00
EBITDA
$ -9.99M$ -2.75M$ -1.09M$ -2.71M$ 4.37M
Operating Income
$ -2.97M$ -2.91M$ -2.59M$ -2.71M$ -2.53M
Other Income/Expenses
$ -7.24M$ 20.86K$ 1.39M$ -219.00K$ 6.90M
Pretax Income
$ -10.21M$ -2.89M$ -1.19M$ -2.93M$ 4.37M
Net Income
$ -10.21M$ -2.90M$ -1.23M$ -2.93M$ 4.37M
Per Share Metrics
Basic EPS
$ -21.50$ -20.00$ -7.50$ -4.12$ 6.50
Diluted EPS
$ -21.50$ -20.00$ -7.50$ -4.12$ 6.50
Weighted Average Shares Outstanding
 475.07K 143.83K 160.25K 688.57K 690.00K
Weighted Average Shares Outstanding (Diluted)
 475.07K 143.83K 160.25K 688.57K 690.00K
Currency in USD

Liminatus Pharma Earnings and Revenue History